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Mycosis fungoides (MF) and Sezary Syndrome (SS) represent the most common subtypes of primary Cutaneous T-cell
lymphoma (CTCL). Patients with advanced MF and SS have a poor prognosis leading to an interest in the development
of new therapies with targeted mechanisms of action and acceptable safety profiles. In this review we focus on such
novel strategies that have changed the treatment paradigm of this rare malignancy.Introduction
Cutaneous T-cell lymphomas (CTCL) are a rare hetero-
geneous group of non-Hodgkin lymphomas derived
from skin-homing mature T-cells. Mycosis fungoides
(MF) and Sezary Syndrome (SS) represent the most
common subtypes of primary CTCL, with an incidence
rate of 4.1/1,000,000 person-years and male predomin-
ance [1]. The prognosis of MF and SS depends on the
age at presentation, type and extent of skin lesions, over-
all stage and presence or absence of peripheral blood in-
volvement and extra-cutaneous disease. In 2007, a
revised staging system of MF and SS by the International
Society for Cutaneous Lymphomas (ISCL)/European
Organization for Research and Treatment of Cancer
(EORTC) was proposed, incorporating stratification of
early stage (TI/T2) into patch alone and both patch and
plaque disease, as well as detailed histologic and molecu-
lar classification of lymph node and peripheral blood in-
volvement leading to a uniform and standardized staging
and classification system [2]. Agar et al. have validated
this new staging system by analyzing the outcome of
1502 MF and SS patients treated at their institution [3].
In this study the median reported follow–up period was
5.9 years (range, 0.4–35.5 years). Seventy one percent of
the patients had ‘limited-stage’ disease (stages IA, IB and
IIA) with median overall survival (OS) ranging between
15.8 to 35.5 years whereas 20 percent of the patients had
‘advanced–stage’ disease (stages IIB, III and IV) and their* Correspondence: oo2130@mail.cumc.columbia.edu
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reproduction in any medium, provided the orOS was inferior ranging between 1.4-4.7 years. This retro-
spective analysis confirmed the previously observed dis-
mal median OS of patients with SS (7% patients in this
study were diagnosed to have SS), which was noted to be
3.1 years in this study from the time of diagnosis [4].
Owing to the heterogeneity and rarity of this neoplasm,
there are few randomized trials to support treatment
recommendations and step-wise treatment algorithms in
various stages of CTCL, particularly advanced stage.
Hence choice of treatment is often determined by phys-
ician or patient preference and is based on several factors,
including stage of disease, use of previous therapies, avail-
ability and side-effect profile of the treatment, duration of
response, patient convenience and expense. Treatment
decisions vary considerably across both US and Europe.
Hence the National Cancer Center Network (NCCN) and
EORTC have published guidelines for the management of
this malignancy that are based on consensus statements
rather than evidence-based data [5,6]. Most experts tend
to start with a single modality or agent of treatment and
add additional therapies at the time of progression based
on consensus recommendations or institutional and indi-
vidual experience. Patients with limited stage disease are
effectively treated with skin-directed therapies; these in-
clude topical nitrogen mustard, corticosteroids, bexaro-
tene, localized radiotherapy or psoralen plus ultraviolet A
therapy, as listed in the NCCN and EORTC guidelines.
Most patients will achieve short-term clinical response
but will have recurrent disease for many years but still
have a normal life expectancy [5-7]. Recurrent disease
after a durable remission can often be retreated with the
same modality. If skin-directed therapies are ineffective or
if the patient develops advanced stage disease then systemic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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bexarotene, photopheresis, denileukin diftitox, vorinostat,
alemtuzumab, cytotoxic chemotherapy, or combination
therapies. In advanced stage disease, responses are often
partial and seldom durable and there is no treatment for
which improved survival has been demonstrated [3,4,8].
Allogeneic stem cell transplant is reserved for selected
young patients with advanced-stage disease in order to ex-
ploit a graft versus lymphoma effect for long-term disease
control. Since most patients require prolonged therapy, the
key to successful disease management is to enhance im-
mune function and minimize immunosuppressive therapies
in order to reduce life threatening infectious complications.
This has led to development of new therapies with targeted
mechanisms of action and acceptable safety profile that
may change the paradigm of treating this disease. Further-
more, clinical trials in MF and SS have suffered from lack
of standardized criteria to assess response and clinical end
points. This has made interpretation of clinical trials in-
volving various agents performed to date cumbersome.
The following consensus guideline was recently proposed
to assess a uniform composite response based on the ISCL,
USCLC and EORTC recommendations to facilitate collab-
oration among investigators: complete remission was
defined as (100% clearance of all skin lesions + all lymph
nodes ≤ 1.5 cm in long axis + normal size of visceral organs
by imaging + ≤ 5% sezary cells in peripheral blood) while
partial remission was defined as [50–99% clearance of skin
lesions, + ≥ 50% reduction in SPD (sum of the product of
the longest bidimensional diameters) + ≥ 50% regression of
measurable disease in the organs + > 50% decrease in
blood tumor burden] [9].
Novel therapeutic agents in cutaneous T-cell lymphoma
While the lack of insight into the biology of CTCL has
hindered the development of true ‘targeted therapies’,
there is now an abundance of new drugs that have
shown potentially significant activity either alone or in
combination with conventional agents.
Histone deacetylase inhibitors (HDAC inhibitors)
Histone deacetylase inhibitors have become a critical
component of the CTCL treatment armamentarium in
the relapsed/refractory setting. These are epigenetic
agents that regulate gene transcription by physical
alterations of either DNA or the structural components
of chromatin. There are 18 HDACs (histone deacety-
lases) discovered in human cells that are divided into
four classes based on their homology to HDACs found
in yeasts. Class I, II and IV HDACs require zinc for their
enzymatic activity, whereas class III HDACs, also known
as silent informant regulator proteins (Sirtuins), require
NAD+ as a coenzyme for their activity. HDAC inhibitors
are a chemically broad group of molecules found toinhibit the activity of HDACs in a wide range of concen-
trations from low nM to high mM. To date, there are
several HDAC inhibitors in development with focus on
greater potency and improved tolerability. The bulk of
the clinical experience with these compounds has fo-
cused on the pan-HDAC inhibitors (i.e., those inhibiting
class I, II and IV enzymes). By causing accumulation of
acetylated histones and non-histone proteins in the cell,
HDAC inhibitors lead to several effects, including tran-
scriptional modification and altered function of proteins
regulating cell proliferation, cell cycle progression, differ-
entiation and apoptosis [10,11]. HDAC inhibitors can
block cell proliferation and cause apoptosis in human
tumor derived cell lines by causing cell cycle arrest in
G1 or G2/M phase with relative sparing of normal cells
through dysregulation of proteins that control cell cycle
progression and coordinate the G1/S and G2/M transi-
tion such as cyclins, cyclin-dependent kinases (Cdk) and
their associated regulators [12-14]. HDAC inhibitors can
also induce upregulation of p21, p27 and p16, which
bind to and inactivate CDK2 and CDK4, hence leading
to inhibition of cell cycle progression [15,16]. HDAC
inhibitors have also been observed to increase the ex-
pression of genes that encode for death receptors and
their ligands, such as Fas and the Apo 2 L/TRAIL recep-
tors, DR4 and DR5, downregulate c-FLIP, c1AP2 and
X1AP and induce generation of reactive oxygen species
(ROS) all of which contribute towards apoptosis [17-22].
Other non-histone targets of HDAC inhibitors include
transcriptional co-regulators, DNA binding transcrip-
tional factors, chaperone proteins, steroid receptors and
DNA repair enzymes [23-25]. HDAC inhibitors have
been shown to have antiangiogenic effects by various
mechanisms, including up-regulation of angiogenesis
inhibitors such as thrombospondin and von-Hippel Lin-
dau factor, as well as downregulation of factors that pro-
mote vasculogenesis, such as VEGF and hypoxia-
induced protein (HIF-[alpha]) [26,27]. Marquard et al.
investigated HDAC expression and histone acetylation
by immunohistochemical staining in 73 patients with
CTCL [28]. The expression of HDAC1, HDAC2, HDAC6,
and acetylated H4 were correlated to histological subtypes
and overall survival. HDAC2 and acetylated H4 were
more common in aggressive forms of CTCLs compared
with indolent CTCLs whereas HDAC6 was associated
with a favorable outcome. Despite these many pleiotropic
effects, it has been difficult to assign a precise mechanistic
basis to any one or more of these drugs in any particular
tumor type. As single agents these drugs appears to have a
class effect in T-cell lymphomas and CTCL in particular.
A brief description of the various HDAC inhibitors cur-
rently in clinical use or trials for CTCL treatment is listed
below. Two agents of this class, vorinostat (Zolinza) and
romidepsin (FK 228, Depsipeptide, Istodax) are approved for
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[29,30].
Vorinostat (Zolinza)
Vorinostat (suberoylanilide hydroxamic acid), is an oral
pan HDAC inhibitor (inhibits class I, II and IV of HDACs)
that was approved by the U.S. FDA for the treatment of
patients with relapsed or refractory CTCL in October
2006 based on response rates [29]. The mean terminal
half- life is 1.45 h. In vitro studies in CTCL cells demon-
strated anti-proliferative action with the half-maximal in-
hibitory concentration IC50 to be in micromolar range
with selective induction of apoptosis of the transformed
T-cells [31]. Kelly et al. conducted a phase I trial of intraven-
ously administered vorinostat in a variety of hematological
and solid malignancies and based on grade 3 and 4
leukopenia and thrombocytopenia, 300 mg/m2/day for
5 days for 3 consecutive weeks was established as the max-
imum tolerated dose (MTD) in patients with hematologic
malignancies [32]. O’Connor et al. conducted two consecu-
tive phase I trials to compare the activity and toxicity of oral
and intravenous formulations of vorinostat [33]. Regardless
of the formulation, vorinostat was well tolerated in patients
with relapsed/refractory lymphomas although the toxicity
was profile was different with fatigue, anorexia, diarrhea and
dehydration being the dose limited toxicities (DLTs) for
patients on oral vorinostat and myelosuppression being the
DLT for patients receiving intravenous vorinostat. This led
to the first single center phase II trial of vorinostat in CTCL
by Duvic et al. where 33 advanced, heavily pre-treated CTCL
patients received 3 different dosages and schedules of vori-
nostat including 400 mg daily, 300 mg twice daily for 3 days
followed by 4 days of rest every week for 4 weeks followed
by 5 days every week and 300 mg twice daily for 14 days
with a week of rest followed by a maintenance dose of
200 mg twice daily [34]. Treatment was continued until the
patient showed signs of progression or toxicity. Based on re-
sponse and toxicity profile a dose of 400 mg daily was identi-
fied as the optimal dose for this patient population. The
overall response rate (RR) was 24.4% with 8 of the 33
patients having partial remission (PR) including 4 of 11
patients with SS. More importantly, 14 of the 33 patients
(42%) reported significant relief from pruritus. The median
time to response was 11.9 weeks, while the median overall
response duration was 15.1 weeks. This dose was chosen for
the subsequent pivotal multicenter phase IIB trial of 74
patients conducted by Olsen et al. in relapsed CTCL which
showed an overall response rate of 29.7%, [(22 of 74, of
which 21 achieved PR and 1 achieved complete remission
(CR)] with and a 29.5% (18 of 61) response rate in patients
with≥Stage IIB disease [35]. Ten of 30 patients with SS
(33%) demonstrated clinical responses. The median time to
objective response was 56 days, though some patients took
up to 6 months to respond. A Post–Hoc analysis of18 patients in the trial with high blood tumor burden
revealed objective blood response in 28% patients (5/18)
and an objective skin response in 44% (8/18) patients [36].
The most common drug-related side-effects observed
during clinical trials included fatigue, GI symptoms
(nausea, vomiting, diarrhea), hematologic (especially
thrombocytopenia and anemia), dysgeusia, anorexia,
weight loss and spasms. Thromboembolism was reported
in 5% of patients and corrected QT interval prolongation
was reported albeit of no clinical relevance. The ease of
schedule, route of administration and the low toxicity pro-
file of vorinostat led to evaluation of combination therap-
ies. Gardner et al. in their case series of 3 patients reported
a clinical response in 1 SS patient when vorinostat was
combined with interferon gamma and photopheresis [37].
Patient had a durable response of 14 months. Vorinostat
is a very promising agent in the treatment of CTCL
and is currently in multiple clinical trials exploring its
combination with other agents such as bortezomib,
lenalidomide and combination chemotherapy.
Romidepsin
Romidepsin a cyclic peptide originally isolated from
the broth culture of Chromobacterium violaceum and
was approved for the treatment of CTCL patients
who have failed at least 1 prior systemic therapy in
November 2009. It is a potent pan HDAC inhibitor
(inhibits class I, II and IV of HDACs) with a terminal
half-life of 2.64 h and is administered intravenously.
In vitro studies have demonstrated cytotoxic effects of
romidepsin in CTCL cell lines with the half–maximal
inhibitory concentration IC50 to be in the nanomolar
range in comparison with micromolar range IC50 of
vorinostat and belinostat [38]. The first phase I clin-
ical trial of romidepsin was conducted in 2001 at the
NCI by Piekarz et al. and included four patients with
refractory T-cell lymphomas (2 patients with SS, 1 patient
with tumor-stage CTCL, and 1 patient with unspecified
peripheral T-cell lymphoma) [39]. Both patients with SS
who were refractory to conventional chemotherapy
agents had a rapid decrease in the percentage of circu-
lating Sézary cells along with improvement in the skin
erythema and edema. There was rapid clearing of all
tumors after six cycles of treatment with romidepsin in
the third patient. This promising activity led to conduc-
tion of two major independent multicenter phase II
trials of romidepsin in patients with pretreated CTCL;
the pivotal, Gloucester Pharmaceuticals initiated GPI-
04-0001 and the National Cancer Institute (NCI)
sponsored, NCI-1312 study [40,41]. The two trials dif-
fered in their enrollment criteria and efficacy assess-
ment tools but romidepsin was administered as a 4-
hour intravenous infusion at the dose of 14 mg/m2
on days 1, 8, and 15 of a 28-day schedule in both
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initiated study, 71 MF/SS patients who had no more
than 2 prior cytotoxic chemotherapy regimens were
enrolled with majority patients having ≥ stage IIB
(87.3%) and 12.7% patients having stage IA-IIA. The over-
all RR for the group of 71 patients was 34% (24/71) with 4
(7%) CRs and 20 (26%) PRs. Stable disease was noted in
26 patients (38%). The median duration of response
(DOR) was notable at 13.7 months (range, 1–66+
months). Among the patients with a major response
(complete or partial), the median time to response
(TTR) was 2 months (range, 1–6 months). The median
time to progression (TTP) was 15.1 months for patients
with a major response and 5.9 months for patients with
stable disease. One of major criticisms of this trial was
the choice of response assessment tools. Disease in skin
or viscera was assessed by Response Evaluation Criteria
in Solid Tumors (RECIST) criteria, lymph node involve-
ment was assessed using International Working Group
Guidelines (IWGG), and bone marrow involvement was
recorded as present or absent, which were considered to
give inaccurate estimates of disease burden in skin or
blood [42,43]. This was corrected in the pivotal, registra-
tion study, GPI-04-0001 which adopted the more compre-
hensive SWAT score for response assessment or in the
case of erythroderma, the 5-point erythroderma score [44-
47]. Of the 96 patients enrolled in the GPI-04-0001 study,
29.2% had stage IB-IIA and 70.8% had ≥ stage IIB similar
to the NCI study. Despite difference in tools adopted by
the two studies for response assessment, results of the
GPI-04-0001 study were remarkably similar to the NCI
study which included an overall RR of 34% (33/96) in-
cluding 6% CR (6/96), median TTR of 1.9 months, me-
dian time to progression (TTP) of 8.3 months and median
DOR of 14.9 months. One of the striking features of both
studies was the long duration of response achieved in most
patients, extending beyond 3 years, in some. Based on the
results of these two single arm studies, romidepsin was
given final approval by the FDA for use in relapsed/refrac-
tory CTCL. Overall romidepsin was well tolerated in both
studies. Nausea (all grades, 52%–56%), asthenia (all grades,
44%), anorexia (all grades, 20%), vomiting (all grades
19%–26%), and aguesia (all grades, 13%) were commonly
seen in patients receiving romidepsin. Most of these ad-
verse events were mild (grade 1 or 2) and were very man-
ageable. Constitutional symptoms of fatigue (all grades,
41%) and fever (25%) have been observed in patients on
romidepsin treatment and has been hypothesized by some
to be cytokine mediated based on the increased levels of
IL-6 detected in post treatment samples of at least two
patients treated with belinostat who had reported severe
fatigue [48]. Lymphopenia and granulocytopenia, regard-
less of causality, occurred in 3% and 8% of patients in the
GPI-04-0001 study versus 55% and 52% of patients in theNCI study. Infection was reported in 45% of cases in both
studies; however, most of these were attributable to dis-
ease and not related to romidepsin. Although asymptom-
atic T-wave flattening was common in the NCI study, the
results of an intensive safety analysis revealed no clinically
significant corrected QT interval prolongation or electro-
cardiographic abnormalities attributable to romidepsin
[49]. Despite these findings from the intensive analysis of
cardiac toxicity data, the package insert dictates that the
drug needs to be administered with caution in patients
with significant preexisting cardiac abnormalities and con-
comitant medications that prolong QT interval or inhibit
CYP3A4 are generally avoided. A topical formulation of
romidespin is currently in clinical trials in limited stage
CTCL.
Belinostat
Belinostat (PXD101) is a hydroxamate pan-histone
deacetylase inhibitor (inhibits class I, II and IV
HDACs) which demonstrates broad anti-neoplastic
activity in vitro with half –maximal inhibitory con-
centration IC50 in CTCL cell lines in micromolar
range. Its half-life ranges between 0.3-1.3 h for intraven-
ous formulation and 1.8-1.9 hours for the oral formula-
tion. Two parallel phase I studies were conducted to
determine the MTD of the intravenous formulation in re-
fractory solid tumors and hematologic malignancies
[48,50]. In the 46 patients with advanced solid cancers that
received intravenous belinostat, MTD was established at
1000 mg/m2/d for 5 days every 3 weeks based on DLTs of
grade 3 fatigue, diarrhea and atrial fibrillation [48]. How-
ever, pharmacodynamic effects of belinostat on his-
tone acetylation were most notable in the first few
hours following intravenous drug administration. Con-
sequently, it was hypothesized that a protracted or con-
tinuous daily oral dosing schedule could be advantageous,
allowing continual target inhibition leading to an evalu-
ation of oral belinostat in an extension of this study men-
tioned later in this section. Stabilization of disease was
observed in a total of 5 of 16 patients (2 patients with dif-
fuse large-cell lymphoma, two patients with chronic
lymphocytic leukemia and 1 myeloma patient) enrolled in
the phase I study by Gimsing et al.which led to its investi-
gation in T-cell lymphomas [50]. An extension of the pre-
viously reported phase I study by Steele et.al. [48] was
performed to explore the feasibility of oral belinostat [51].
In this study, 15 patients who had previously received
intravenous belinostat were administered oral belinostat
in a range of doses (900–1000 mg/m2) and schedules
(once, twice or thrice daily), on either day 1 or days 1–5
every 3 weeks. Doses as high as 1000 mg/m2 for 5 con-
secutive days was tolerated. The estimated fasting bio-
availability was 15 – 35%. Of interest, level of target
inhibition (i.e. histone acetylation) was similar to that
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assessed in a further study of 92 patients where a var-
iety of schedules were investigated [52]. Based on
DLTs, the recommended phase II doses for oral for-
mulation were: (i) 250 mg daily and twice a day for
28 days (ii) 750 mg on days 1 – 14, every 21 days;
and (iii) 2000 mg on days 1 – 5, every 21 days. Fur-
ther dose escalation studies beyond 2000 mg are on-
going and the highest dose for the day 1–5 dosing is
yet to be determined. A multicenter phase II trial by
Pohlman et al. evaluated the activity of belinostat in
patients with PTCL or CTCL who had failed 1 prior
systemic therapy. Belinostat (1000 mg/m [2]) was
administered as a 30-min IV infusion on days 1–5 of
a 3 week cycle [53]. Twenty nine patients in the CTCL
arm (including 15 MF, 7 SS, 5 non-MF/SS and 2 unclassi-
fied) were enrolled with majority (55%) having stage IV dis-
ease and were treated for a median of 2 cycles (range, 1–6).
Four responses were observed (14%) with 2 CR (Anaplastic
large cell lymphoma and MF), 2 PR (MF and SS) and 16
stable-disease (SD). The median duration of the response
was 273 days (range, 48–469+). Pruritus relief was noted in
7 out of 14 patients. Of interest median time to response
and relief of pruritus was short of 16 days. Overall in both
study arms the drug was well tolerated and most adverse
events were only grade 1/2 (nausea, fatigue, constipation,
diarrhea, and vomiting). There were 4 grade 3/4 AEs that
included peripheral edema, adynamic ileus, pruritus and
rash. No significant hematologic or cardiac toxicity was
observed. Belinostat’s activity as monotherapy has been
most marked in the lymphoid malignancies and in particu-
lar, relapsed or refractory PTCL and CTCL; as a result the
FDA granted belinostat orphan drug status for PTCL, and
a pivotal phase II registration trial (the BELIEF study) for
this tumor type is underway.
Panobinostat
Panobinostat, also known as LBH589, is an oral pan-
HDAC inhibitor (inhibits class I, II and IV HDACs)
belonging to the hydroxamic acid group that has shown
activity in patients with CTCL in a phase I and II trials
[54,55]. It has a long half-life of 8 h and exerts potent
cytotoxic effects in CTCL cell lines with an IC50 in
nanomolar range similar to romidepsin. Duvic et al. con-
ducted an open label multicenter phase II trial with the
primary objective of establishing the efficacy and safety
of panobinostat for patients with relapsed/refractory
CTCL with Stage IB–IVA MF and SS [55]. Ninety five
patients (70 with MF and 25 with SS) were enrolled who
had received 3–4 median prior treatment regimens and
mostly were ≥ Stage IIB at study entry. They received a
median of 3 (range, 1–17+) treatment cycles of panobi-
nostat. Eleven out of 62 patients who had received prior
bexarotene therapy had confirmed skin responses bymodified SWAT (mSWAT), including 2 complete skin
responses and were awaiting CT scans to assess systemic
response. Four of the 33 bexarotene naïve patients had
confirmed skin and CT scan responses. Common ad-
verse events (>20%; all grades regardless of causality)
included diarrhea, thrombocytopenia, nausea, pruritus,
fatigue and asthenia while Grade 3/4 AEs (>2%, regard-
less of causality) included thrombocytopenia, neutro-
penia, pruritus, diarrhea, and hypophosphatemia. Based
on this trial, panobinostat demonstrated encouraging ef-
ficacy with good tolerability in MF and SS patients po-
tentially making it an attractive alternative HDAC inhibitor
in the treatment of CTCL. A mechanistic study of panobi-
nostat showed that this agent induces CXCR4 degradation
via the proteasomal pathway and has synergy with CXCR4
inhibition, supporting the rationale for testing such a com-
bination in vivo [56]. It is being evaluated in several
hematologic malignancies including T-cell lymphomas in
combination with conventional chemotherapy agents, pro-
teasome inhibitor, bortezomib and m-TOR inhibitors, ever-
olimus and RAD001.
Future direction of HDAC inhibitors in CTCL
The biological basis for the remarkable clinical activity of
HDAC inhibitors in CTCL remains elusive. We anticipate
more scientific and translational studies to dissect the mo-
lecular mechanisms behind this high efficacy and favorable
tolerability. Given the plethora of HDAC inhibitors dem-
onstrating promising but variable activity in CTCL, we an-
ticipate that future clinical trials of HDAC inhibitors will
incorporate detailed molecular analysis of the tumors to
identify predictive biomarkers of response or resistance to
individual agents or as a class to enable delivery of perso-
nalized therapy. One such example is the increased expres-
sion of phospho-NF-ĸB p65 and phospho-STAT-1
demonstrated in a vorinostat resistant cell line (called as
HH/VOR, generated by exposing the vorinostat sensitive
HH cell line to increasing concentations of vorinostat)
[57]. Using a genome-wide loss of function screen with a
short hairpin RNA (shRNA) library, HR23B, a component
of the proteasome, was identified as a determinant of
HDAC inhibitor sensitivity [58]. HR23B is expressed at
high levels in CTCL, and there was a correlation between
HR23B expression and clinical response to HDACis [59].
Presently there are no trials comparing one HDAC inhibi-
tor with another and hence while romidepsin appears
most promising it cannot be definitively concluded that it
is superior to other HDAC inhibitors. Of note, unpub-
lished anecdotal evidence suggests lack of cross-resistance
across the spectrum of HDAC inhibitors in the treatment
of CTCL. However this needs prospective validation in a
randomized clinical trial. Currently, HDAC inhibitors can
be used as single agents after the failure of at least one to
two systemic therapies for as long as there is clinical benefit
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physicians like to use them before use of chemotherapy
agents given the high efficacy and acceptable tolerability.
Unfortunately at the moment there are no clinical guide-
lines on how to use them best during the course of this
chronic malignancy. As data regarding HDAC inhibitor
combinations with conventional chemotherapy agents,
hypomethalating agents, proteasome inhibitors and radi-
ation become available; it is likely that the addition of an-
other agent at progression will become a standard of care.
Anti-folate antagonist
Pralatrexate (Fotolyn)
Pralatrexate (PDX, 10-propargyl 10-deazaaminopterin), a
novel antifolate designed to have high affinity for the
reduced folate carrier (RFC) was approved for the treat-
ment of relapsed or refractory PTCL in September 2009
based on the pivotal multicenter international registration
study PROPEL which demonstrated an overall RR of 29%
(32/109), including 12 (11%) CRs and 20 (18%) PRs [60].
Pralatrexate is also a more effective substrate for polygluta-
mation by FPGS so it is more efficiently polyglutamated
compared to methotrexate which subsequently leads to
higher intracellular accumulation of the drug compared to
methotrexate which also enhances its affinity for dihydrofo-
late reductase (DHFR) [61-63]. Analysis of 12 patients with
refractory transformed MF in the PROPEL study demon-
strated a 58% objective RR using International Workshop
Criteria [64]. The significant activity observed in this group
led to the dose finding multicenter study that initially en-
rolled 31 patients with relapsed/refractory MF, SS and pri-
mary cutaneous anaplastic large–cell lymphoma into 6
cohorts at varying dose and schedule and established the
optimal dose and schedule as 15 mg/m2 weekly for 3 out
of 4 weeks based on grade 3 mucositis [65]. Based on the
mSWAT score, an overall RR of 43% (12/28) was observed
at the above stated optimal dose. This highlighted promis-
ing activity of this agent and the toxicity profile suggested
that it could be given for prolonged time periods to sustain
responses. Toxicity was mild and consisted of grade 1 and
2 adverse events (AEs) included fatigue (34%), mucositis
(28%), nausea and edema (24%), epistaxis (21%), pyrexia
(17%), anemia (14%), etc. A phase II trial of pralatrexate in
combination with bexarotene in relapsed/refractory CTCL
is ongoing. Recently Marchi et al. demonstrated synergy of
pralatrexate with proteasome inhibitor bortezomib in pre-
clinical models of T-cell lymphoma laying the platform for
development of further combination therapies of pralatrex-
ate with other active agents T-cell lymphoma [66].
Proteosome inhibitors
Bortezomib (Velcade)
The proteasome inhibitor bortezomib is a dipeptide boro-
nic acid analog that reversibly inhibits the chymotrypticactivity of the 20S subunit of the proteasome. Bortezomib
targets the catalytic 20S core of the proteosome with a
multitude of downstream effects including inhibition of
cellular protesosome, accumulation of the cell cycle-
dependent kinase inhibitors such as p27/p21, activation of
p53, inhibition of NF-kB and accumulation of pro-
apoptotic proteins like Noxa which inactivates anti-
apoptotic proteins like McL-1 [67]. Bortezomib is the first
agent of this class to be approved for the treatment of
multiple myeloma and mantle cell lymphoma [68,69]. It
has been hypothesized that cancer cells are more
dependent on the proteasome for clearance of abnormal
or mutant proteins [70]. In fact, several preclinical studies
have shown that malignant cells are more sensitive to pro-
teasome inhibition than normal cells [71-75]. Bortezomib
has an elimination half-life of 9 to 15 h. Zinzani et al. con-
ducted a phase II trial of bortezomib (1.3 mg/m2 on days
1,4, 8, and 11 of a 21-day cycle) in 15 patients with
relapsed/refractory T-cell lymphoma, including PTCL
(2 patients) or CTCL (10 patients all MF, no SS) with a
reported overall response rate (ORR) of 67% (with 2 CR’s
and 6 PR’s) [76]. Among the CTCL patients who received
a median of 6 cycles, there was a RR of 70% (7 of 10) to
bortezomib. One CR (10%) lasted for more than
12 months and 6 PR (60%) were observed. The responses
were also durable in CTCL patients, ranging from 7 to
14 months even in patients with PR’s. The most common
dose limiting side-effects with bortezomib are myelosup-
pression (neutropenia and thrombocytopenia) and sensory
neuropathy that occurred in 30-40% patients with mye-
loma and 50% of patients with CTCL treated with borte-
zomib. Most patients had improvement or resolution of
symptoms off drug. A phase I study evaluated the use of
standard dose CHOP (cyclophosphamide, doxorubicin, vin-
cristine, and prednisone) plus bortezomib in 13 patients
with advanced, aggressive T-cell or NK/T-cell lymphoma
[77]. No dose limiting toxicities were observed up to the
maximal dose of bortezomib of 1.6 mg/m2. The CR rate
was 62%. No data were provided for progression free or
overall survival. Thus while experience with the use of bor-
tezomib in patients with CTCL is limited, the responses
observed are durable and toxicity was acceptable. We an-
ticipate that carfilzomib, the new selective irreversible epox-
yketone 20S proteasome inhibitor which causes minimal
neuropathy and demonstrates promising activity in both
bortezomib naïve and treated myeloma patients will be
soon evaluated in T-cell lymphoma patients including
CTCL [78-80]. Several preclinical studies and early phase
clinical trials have explored the feasibility, efficacy and tox-
icity of bortezomib and HDACis in several malignancies
such as multiple myeloma, acute myeloid leukemia, myelo-
dysplastic syndrome, mantle cell lymphoma, CLL and a
host of solid tumors and demonstrated response with min-
imal toxicity. However given pleiotropic effects of both
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biologic rationale for synergy. Nevertheless, there are mul-
tiple ongoing trials exploring the efficacy and toxicity of
bortezomib in combination with multiple HDACis in
CTCL and we hope that molecular co-relates from these




Forodesine is a transition state purine nucleoside pho-
phoryalse inhibitor (PNP). Inhibiton of this enzyme
leads to T-cell selective intracellular accumulation of
dGTP resulting in apoptosis and cell cycle arrest. An
open-label phase I dose-escalation study of oral foro-
desine (40 to 320 mg/m [2]) given daily for 4 weeks
was conducted by Duvic et al. [81]. The primary ob-
jective was to determine the maximum and optimal
tolerated dose with assessment of response by
mSWAT. Nine of an intended 64 patients were avail-
able for evaluation when the initial results were
reported at the ASCO 2009 annual meeting. All 9 had
completed > 12 months of treatment with ongoing
responses in at least 3 of them ranging from 416–863 days.
Of the 9 patients, 2 patients attained CR, 3 achieved a PR
and 4 had stable disease (SD). The most common related
adverse events were nausea (44%), fatigue, peripheral
edema, dyspnea, and urinary casts (22%). Two of the 9
patients experienced treatment related grade 3 or higher
peripheral edema and diffuse large B-cell lymphoma.
Hematologic toxicity and infections related to the forode-
sine were not seen. Forodesine definitely shows acceptable
tolerability in patients with T-cell lymphoma, is conveni-
ent in administration (oral) and has efficacy on extended
duration of therapy (>12 months). A phase II study of for-
odesine monotherapy is ongoing in patients with relapsed
and refractory CTCL patients.
Monoclonal antibodies
Anti-CD52 (Alemtuzumab)
Alemtuzumab or Campath-1H is a recombinant DNA-
derived humanized IgG1 kappa monoclonal antibody
that is directed against CD52, a 21–28 kDa cell surface
glycoprotein that is expressed on mature lymphocytes.
Ginaldi et al. investigated the intensity of expression of
CD52 in a study of 45 cases [24 cases of B-cell chronic
lymphocytic leukemia (CLL), 21 cases of T-cell prolym-
phocytic leukemia (T-PLL) and 12 normal controls] and
showed that normal T lymphocytes expressed higher
CD52 expression than B lymphocytes and that the anti-
gen was also significantly higher in T-prolymphocytic
leukemia (T-PLL) compared with CLL [82].Of interest,
the level of CD52 expression was somewhat higher in
patients who responded to alemtuzumab than in non-responders which might provide a rationale as to why
patients with T-PLL had better response in comparison
with patients with CLL. Alemtuzumab is administered as
an infusion over 2 h in a dose escalation manner starting
at a dose of 10 mg three times a week and increased up to
30 mg thrice per week for a total of 12 weeks depending
upon tolerability. Responses are evaluated at the end of
the 12 weeks. Several reports of promising activity have
been reported in patients with MF and SS albeit with
small number of patients [83-87]. A phase II study was
conducted by Lundin et al. which included 22 patients
with refractory, ‘advanced-stage’, and CD52 positive CTCL
with an overall RR of 55% (32% CR, 23% PR) including
clearing of sezary cells in 6 out of 7 patients and better
responses in erythrodermic patients over those with pla-
ques or skin tumors [85]. There is a great deal of variabil-
ity between definitions of SS in some of the earlier studies
making difficult to interpret results. However, in studies
where SS is clearly defined per the revised ISCL criteria,
an overall RR between 82-100% with CR of 21–100% has
been demonstrated with a DOR ranging from <3 months
to > 12 months. Most of these studies are either retro-
spective, single institution based case series or phase II
studies with very small number of patients treated (for ex-
ample, n = 6). Despite the potent anti-tumor activity, pro-
found immunosuppression secondary to this agent
remains of significant concern and infectious complica-
tions including bacterial sepsis and CMV reactivation have
been observed in two-thirds of treated patients with alem-
tuzumab. Careful monitoring for CMV reactivation and
appropriate prophylaxis for PCP/HSV/VZV is recom-
mended for patients treated with alemtuzumab. Subcuta-
neous (SQ) administration of this agent has also been
explored to reduce toxicity and has been shown to dem-
onstrate better tolerability with similar peak drug concen-
trations achieved but at a higher cumulative dose, and a
higher potential to develop anti-alemtuzumab antibodies
compared with intravenous dosing [88]. Alinari et al. fur-
ther assessed the tolerability of SQ alemtuzumab in 5 eld-
erly SS patients with multiple co-morbidities who were
administered SQ alemtuzumab with dose escalation from
3–30 mg over 5–7 days followed by 30 mg thrice a week
for 5–9 weeks [89]. An overall response rate of 100% with
4 unconfirmed CR’s and 1 complete CR (clearance of skin
lesions also) was observed along with rapid relief from
pruritus and rapid clearance of tumor cells from blood.
No grade 3 & 4 hematologic toxicity was observed. Two
asymptomatic CMV reactivations and one asymptomatic
low-level EBV reactivation were noted both of which
cleared with 2 weeks of oral valganciclovir or valacyclovir.
While the number of patients in this report is small, it
demonstrates that SQ administration of alemtuzumab is
well tolerated despite advanced age and poor performance
status. In another attempt to reduce the incidence of
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by Zinzani et al. assessed the impact of a reduced dose
(10 mg three times per week for four weeks) schedule in
10 patients with pretreated cutaneous/peripheral T-cell
lymphoma [90]. Of these, 6 had nodal PTCLU and 4 had
MF. All MF patients who were also co-treated with beta-
methasone were in stage T3 or T4. In the MF subset, the
best response was a PR that was seen in 3 of the 4 patients
(75%) with no≥ grade 3 hematologic toxicity. Bernengo
et al. further explored the efficacy of low dose SQ alemtu-
zumab in 14 SS patients (11 relapsed and 3 untreated)
[91]. Four received 3 mg alemtuzumab on day 1, 10 mg
on day 3, then 15 mg on alternating days. A reduced dos-
age (3 mg on day 1, then 10 mg on alternating days) was
administered to the remaining patients. Overall, 12 of
the14 patients (85.7%) achieved a clinical response, with 3
complete responses (21.4%) at a median follow-up of
16 months with TTF of 12 months. No patient in the
group treated with 10 mg developed hematologic toxicity
or infections while 28% patients experienced infectious
complications at dose ≥15 mg. Thus this study demon-
strated that low dose intermittent SQ alemtuzumab
(10 mg maximum per administration) induced favorable
outcomes with durable responses and benefit of reduced
incidence of infectious complications making this an at-
tractive option.
Anti-CD4
CD4 belongs to the immunoglobulin superfamily and
acts as a co-receptor of TCR (T-cell receptor). It is nor-
mally expressed in helper T-cells, regulatory T-cells,
macrophages, monocytes and dendritic cells and highly
expressed by T-cell malignancies including PTCL’s and
CTCL’s. Different monoclonal antibodies against T-cell
antigens have been developed and evaluated clinically
with limited success in T-cell lymphomas. Knox et al.
reported results with SK3, a chimeric non-depleting
anti-CD4 monoclonal antibody, in 7 patients with MF
where the antibody was administered IV two times per
week for 3 consecutive weeks at either the 10, 20, 40, or
80 mg dose [92]. No patient in the group treated with
10 mg developed hematologic toxicity or infections. Two
objective responses were observed at the highest dose
group. The trial was limited by the development of
antichimeric antibodies. M-T412, an anti-CD4 chimeric
antibody directed against a different epitope of the CD4
molecule, demonstrated a higher affinity and was able to
induce CD4 positive lymphocyte depletion through an
Fc-mediated mechanism. This was studied in 8 MF
patients where patients received a single IV administration
of 50, 100 or 200 mg and showed an objective response in
5 patients with freedom from progression lasting 25 weeks
[93]. The antibody was well tolerated with clinical efficacy
and low level of immunogenicity but with a weak signal ofactivity. One of the more promising anti CD4 antibodies
is Zanolimumab (HuMax), a fully humanized anti-CD4
monoclonal antibody that is specific for the CD4 receptor
expressed on most T lymphocytes and to a lesser extent
on macrophages. Kim et al. conducted two identical pro-
spective, multicenter, phase 2 studies (Hx-CD4-007 and
Hx-CD4-008) in patients with relapsed/refractory CTCL
in ‘early-stage’ and ‘advanced-stage’ respectively [94].
Thirty-eight patients with MF and 9 patients with SS were
treated with 17 weekly infusions of zanolimumab (early-
stage patients, 280 and 580 mg; advanced-stage, 280 and
980 mg) with assessment of response by CA score (com-
posite assessment of index lesion disease severity). Thirteen
objective responses were observed in the MF and 2 in the
SS group respectively. Duration response was 12–24 weeks
in the MF patients in the low dose group. High response
rates up to 56% were noted in the high dose group with
median response duration of 81 weeks. Most common
treatment related AEs included inflammatory skin reac-
tions and infections of the skin and upper respiratory tract.
Of the 9 infections related to the drug, the majority was
grade 2 or less and felt to be secondary to profound deple-
tion of CD4+ lymphocytes. Thus zanolimumab demon-
strated encouraging responses even though the duration of
response is short. It is currently being tested in a pivotal
phase III multicenter study in the US in MF and SS
patients who are intolerant or refractory to bexarotene and
one other standard therapy.
Anti-CD30
CD30 or the Ki-1 antigen is a cell surface leukocyte acti-
vation transmembrane protein of 120 kDa belonging to
the TNF receptor superfamily that can be shed in a sol-
uble form. It is expressed on mitogen activated B and T
lymphocytes but not on resting monocytes and lympho-
cytes making it an attractive target. It is also expressed
on malignant hematopoietic cells including Hodgkins
lymphoma, ALCL, primary cutaneous ALCL, lympho-
matoid papulosis and certain cases of transformed MF
and is an attractive agent for therapy. Although the
function of CD30 has not been clearly defined, it has
been implicated in both cell death and proliferation [95].
In the normal physiologic state, CD30 cell surface ex-
pression is limited to activated T, B, and natural killer
lymphocytes. Because CD30 serves as a diagnostic mar-
ker for the CD30 lymphoproliferative disorders, has a
limited expression profile on normal cells and tissues,
and has apoptosis-inducing characteristics, it has been
evaluated as a target for immunotherapy [95,96]. Results
of early generation naked monoclonal antibodies target-
ing CD30 have been disappointing due to their poor
antigen binding properties, ineffective activation of ef-
fector cells, and neutralization by soluble CD30 [96-98].
SGN-30, is a humanized chimeric more potent CD30
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distinct from other anti-CD30 antibodies [95]. In pre-
clinical studies, SGN-30 induced growth inhibition of
Hodgkin’s lymphoma and ALCL cell lines in vitro and
has shown potent antitumor activity in xenograft models
of disseminated and localized Hodgkin’s lymphoma and
ALCL [95]. It was evaluated by Duvic et al. in a multicen-
ter phase II trial in heavily pretreated CD30-expressing
cutaneous tumors including primary cutaneous anaplastic
large cell lymphoma (pc-ALCL), lymphomatoid papulosis
and transformed MF (t-MF) [99]. The initial dose was
4 mg/kg given every 3 weeks, which was later increased to
12 mg/kg. Of the 3 patients with t-MF, 1 achieved a PR, 1
demonstrated SD while one failed to respond. Duration of
response in the patient achieving PR was 84 days and
side-effects were minimal highlighting its antitumor activ-
ity and tolerability in CTCL patients.
SGN-35 (Brentuximab Vedotin)
SGN-35 is a drug-antibody conjugate in which SGN-30 is
linked to monomethylauristatin E (MMAE), a synthetic
antitubulin agent to enhance antitumor activity. After
binding CD30, the conjugate is rapidly internalized inside
the cell through CD30 receptor mediated endocytosis
where it binds to tubulin and initiates cell cycle arrest.
Two phase I studies have been conducted evaluating effi-
cacy and tolerability of two different schedules (every
3 weeks or weekly). In the first dose-escalation trial con-
ducted by Younes et al., 45 patients with refractory or re-
current CD30-positive hematologic malignancies, including
HL (n=42), systemic anaplastic large cell lymphoma
(sALCL; n=2), and angioimmunoblastic T cell lymphoma
(n=1) were treated on an every 3 week basis [100]. Ap-
proximately 75% of patients reporting B- symptoms at
baseline experienced symptom resolution on study. Most
patients (86%) had reductions in target lesion size. Among
28 evaluable patients treated at doses 1.2 mg/kg every
3 week, the objective response rate (CR+PR) was 46%
(n=13) and the complete remission rate was 25% (n=7).
Two additional PRs were observed in the 0.6 mg/kg cohort.
Median response duration to date was 22 weeks (range, 0.1
+ to 38+ weeks). Thirteen patients continued to remain on
the study. The most common adverse events (occurring in
20% of patients) were fatigue, pyrexia, nausea, and diarrhea.
To assess if more frequent dosing might maximize anti-
tumor activity with acceptable tolerability, Bartlett et al.
conducted the second multicenter, phase I, weekly dosing,
dose-escalation study in 37 patients with refractory or re-
current HL or systemic ALCL [101]. The objective RR was
46% (16 of 35) with 29% of patients (10 of 35) achieving
CR. Dose-limiting toxicities included grade 3 diarrhea and/
or vomiting and grade 4 hyperglycemia. These remark-
able results led to 2 phase II studies, one with
Hodgkin disease and the other with systemic ALCL.In the first study of 102 patients with relapsed
Hodgkin lymphoma, an overall RR of 75% was
observed (76 of 102) with 34% (n = 35) CR’s [102]. In
the second phase II study of 58 patients with
relapsed systemic ALCL, overall RR of 86% (50 of
58) with 53% CR’s were noted [103]. These impres-
sive results led to accelerated approval of brentuxi-
mab vedotin for the treatment of relapsed and
refractory Hodgkin lymphoma and ALCL. This
promising activity has led to several trials exploring
the use of this agent in other CD30 expressing
lymphomas including CTCL. MF and SS have vari-
able expression of CD30 and hence a phase II single
arm open label exploratory study evaluating the bio-
logic effects of brentuximab vedotin in patients with
CTCL is currently ongoing where patients regardless
of their levels of CD30 expression (low, intermediate
and high based on immunohistochemical studies)
will be enrolled. In the future, there will be studies
combining this with other modalities.
Other novel targets
Pegylated liposomal doxorubicin (CaelyxTM) Some
patients with advanced-stage CTCL are treated with
chemotherapy regimens like CHOP where response rates
range between 40-70%. Pegylated Liposomal Doxorubi-
cin (PLD) is an antineoplastic antibiotic with biologic ac-
tivity similar to daunorubicin but with the added
advantage of longer circulation time and higher intratu-
moral drug concentration levels leading to potentially
higher target specificity and lower rate of infectious
complications secondary to myelosuppression and cardi-
otoxicity. Dummer et al. conducted the EORTC 21012,
phase II multicenter trial of PLD in 49 steroid naïve
relapsed and refractory advanced MF patients that
demonstrated a RR of 40.8% (20 of 29) including 6%
CR’s (n = 3) and 34.7% PR (n = 17) [104]. The drug was
considered safe for administration with the following ≥
grade 3 toxicity: 2% cardiac toxicity, allergy (2%), 4%
constitutional symptoms, etc. No severe hematological
toxicity or infections were seen. Duration of response
and efficacy in SS patients are unknown. These results
are encouraging and warrant further investigation.
Enzastaurin (LY317615) Enzastaurin is a novel oral
Protein kinase C (PKC) inhibitor that plays a role in cell
survival, growth factor response, proliferation and angio-
genesis. In vitro studies demonstrated apoptotic activity in
two CTCL cell lines (HH and Hut-78) mediated via the
AKT signaling and caspase pathways which led to its phase
I trial in patients with advanced malignancies that estab-
lished the MTD at 525 mg orally [105,106]. Querfeld at al.
conducted the phase II multicenter trial of enzastaurin in
patients with relapsed/refractory MF (IB-IVB) and SS [107].
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in 1 MF patient with an overall RR of 5% by composite re-
sponse evaluation. There were no CR’s. Although 17
patients with MF and 4 patients with SS had SD, the me-
dian time to progression (TTP) was only 78 days in MF
patients and 44 days in SS patients. Accrual was terminated
early due to lack of response. About 25% of the enrolled
patients had meaningful pruritus relief. The authors con-
cluded that it might be worth combining enzastaurin with
other active agents to enhance its efficacy given its favorable
toxicity profile.
TLR9 agonist vaccine Toll-like receptor (TLR) agonists
represent a novel mechanism of stimulating and enhan-
cing the host’s innate and adaptive immunity to the skin
homing tumor cells. Phase I/II studies in indolent B-cell
lymphoma demonstrated that when local radiation to ex-
pose tumor antigens was combined with intratumoral in-
jection of TLR-9 activating CpG-oligodeoxynucleotide (to
serve as an in situ vaccination maneuver), meaningful clin-
ical responses were observed in 4 of 15 patients (27%) with
one attaining CR and safe tolerability [108]. The same ap-
proach was then applied to patients with MF in a phase I/
II trial by Kim et al. where 15 patients with relapsed/re-
fractory disease were treated with local low dose radiation
followed by immediate and weekly intratumoral injections
of CpG enriched oligodeoxynucleotide with assessment of
response by mSWAT score [109]. The treatment was very
well tolerated with only 1 grade 3 AE that included focal
skin necrosis due to injection site reaction. Five of the 14
evaluable patients demonstrated a PR with 1 near PR
mounting an overall RR close to 35% thereby demonstrating
that in situ vaccination strategy combined with low dose ra-
diation in MF warrants further investigation as it is a feasible
option with acceptable toxicity.
Immunomodulatory agents Lenalidomide (3-(4′aminoi-
soindolin-1′-one)-1-piperidine-2, 6-dione (RevlimidW) is
one of the novel immunomodulatory (IMiDs) agents which
was granted FDA approval for treatment of myelodysplastic
syndromes associated with 5q deletion cytogenetic abnor-
mality and relapsed/refractory multiple myeloma. IMiDs are
structural and functional analogs of thalidomide that were
specifically designed to enhance immunomodulatory and
anticancer properties with better tolerability profiles. Lenali-
domide, a second generation IMiD, was created using thal-
idomide as a template by adding an amino group to the 4th
carbon of the phthaloyl ring and removal of a carbonyl
group. This novel drug has several proposed mechanisms of
action including immunomodulatory, antiangiogenic, and
direct apoptotic properties, which culminate in cancer cell
death either through direct interference with key functions
of tumor cells or indirectly through modulation of signaling
pathways that regulate their interaction to bone marrowstromal cells. While recent preclinical and clinical studies
put forward a dual mechanism of action for lenalidomide,
involving both a direct tumoricidal activity and immuno-
modulation. It is difficult to assign a specific mode of ac-
tion to any specific tumor type. PK data indicates that the
mean half-life of elimination increases with increasing
dose, from approximately 3 h at the 5 mg dose up to ap-
proximately nine hours at the 400 mg dose. Steady state
levels are achieved by day 4. Cytopenias are the primary
adverse events associated with the administration of lena-
lidomide, particularly in subjects with compromised bone-
marrow. However, these are manageable with dose inter-
ruptions and reductions. This agent has been studied in
lymphoproliferative disorders. Querfeld et al. conducted a
phase II trial of lenalidomide in relapsed/refractory MF
and SS patients where 15 patients were treated with
25 mg of oral lenalidomide daily for 21 days followed by
1 week of rest [110]. Response was assessed after every
cycle using Composite Assessment (CA) of Index Lesion
Disease Severity for skin lesions, absolute Sézary cell count
for quantification of circulating malignant lymphocytes
and/or CT scans for evidence of adenopathy or visceral
disease. Five patients achieved a partial response (defined
as a CA ratio less than or equal to 0.5 with no new clinic-
ally abnormal lymph nodes, no progression of existing
clinically abnormal lymph nodes, and no new cutaneous
tumors). Six patients demonstrated minor responses such
as regression of cutaneous tumor lesions, improved lymph-
adenopathy, and skin improvement from initial generalized
erythroderma to less severe erythema with less scaling. Four
patients experienced progression of disease. The most com-
mon side effects were anemia, fatigue/malaise, skin burn-
ing, pruritus, and lower leg edema. An initial flare
phenomenon (manifested by increase in skin lesions, lymph
node swelling, increase in blood tumor burden etc.) the
biological basis of which is poorly understood was noted in
almost all patients during the first cycle or beginning of
each cycle with subsequent resolution during the course of
treatment. This study while limited by the number of
patients revealed encouraging activity and tolerable toxicity
profile. Its role as monotherapy in relapsed/refractory
CTCL is further being assessed in a larger single institution
phase II study using updated and standardized clinical end-
point criteria such as the mSWAT. Given the chronicity of
CTCL treatment and its established potential in multiple
myeloma, its role as a maintenance regimen following sys-
temic chemotherapy (gemcitabine or doxil) in advanced
stage CTCL patients is being explored in a pivotal EORTC
initiated phase III trial.
Conclusions
At present there are many promising agents with activity
against cutaneous T-cell lymphomas as summarized in
Table 1. However establishing a definitive diagnosis,




















































































Class I, II, IV
HDAC inhibitor
Phase II 1000 mg/m2
on days, 1-5 every
3weeks















Class I, II, IV
HDAC inhibitor
Phase II 20mg orally on
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Table 1 Summary of Major Clinical Trials of Novel Drugs in CTCL (Continued)
Bortez-
omib
Various Phase II 1.3 mg/m2
on days 1,4, 8
and 11 every
21 days


















Phase I Dose finding
study 40–320 mg/m2
oral daily















Phase II Escalating dose
up to 30 mg
thrice/week









































































IMiD Phase II 25 mg orally daily
for 21 days followed by
1 week of rest
15 Not
available
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priate initial therapy still remains critical. High response
rates and favorable toxicity profile of HDAC inhibitors
has become the cornerstone of treatment of advanced
and relapsed/refractory CTCL. Future clinical trials would
focus on utilizing these novel effective agents early in
the course of this neoplasm thereby forming a backbone
to which sequential therapies could be added in an esca-
lated rational step-wise approach. Designing and imple-
menting well designed clinical trials with careful thought
to correlative molecular studies will become the dogma
of clinical investigators and will equip clinicians to de-
liver personalized treatment. This hopefully will help
move the field forward towards a cure of these diseases,
as treatment currently remains largely palliative for most
patients with CTCL.
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